ADMA Stock Overview
A biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ADMA Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.63 |
| 52 Week High | US$9.78 |
| 52 Week Low | US$3.06 |
| Beta | 0.43 |
| 1 Month Change | 55.32% |
| 3 Month Change | 83.08% |
| 1 Year Change | 138.96% |
| 3 Year Change | 459.88% |
| 5 Year Change | 119.36% |
| Change since IPO | 12.90% |
Recent News & Updates
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13
Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Recent updates
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02ADMA Biologics: Turning A Corner
Nov 20ADMA: Insiders Showing Their Cards
Nov 02ADMA Biologics: Recent Significant Developments And Their Implications For The Stock
Aug 22ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report
Aug 14Shareholder Returns
| ADMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.8% | 0.07% | -0.2% |
| 1Y | 139.0% | 6.9% | 28.2% |
Return vs Industry: ADMA exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: ADMA exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| ADMA volatility | |
|---|---|
| ADMA Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ADMA's share price has been volatile over the past 3 months.
Volatility Over Time: ADMA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 624 | Adam Grossman | www.admabiologics.com |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
ADMA Biologics, Inc. Fundamentals Summary
| ADMA fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | -US$3.64m |
| Revenue (TTM) | US$283.18m |
7.9x
P/S Ratio-612.6x
P/E RatioIs ADMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADMA income statement (TTM) | |
|---|---|
| Revenue | US$283.18m |
| Cost of Revenue | US$169.54m |
| Gross Profit | US$113.64m |
| Other Expenses | US$117.28m |
| Earnings | -US$3.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 40.13% |
| Net Profit Margin | -1.29% |
| Debt/Equity Ratio | 85.1% |
How did ADMA perform over the long term?
See historical performance and comparison